The latest performance of 270 pharmaceutical companies, 7 of which made a steady profit of over 3 billion in the whole year!

Medical network on November 5 news at present A-share half year report closed, in general, the vast majority of pharmaceutical companies have earned! ▍ the third quarter ended According to incomplete statistics, 270 pharmaceutical enterprises had issued the third quarter performance report as of November 1 The total operating revenue was more than 1 trillion yuan, achieving a net profit of 93.1 billion yuan, with an average net profit margin of 8.72% Among the 270 enterprises, there are only 8 loss making enterprises, accounting for about 3% of the total number of statistical pharmaceutical enterprises, with a loss of 2.2 billion yuan, an increase of about 1 billion yuan compared with the loss reported in half a year The number of profitable enterprises is 262, accounting for 97%, with a profit of 95.368 billion yuan, an increase of 38 billion yuan over the medium term (see the detailed performance list of 270 pharmaceutical companies at the end of the article.) Note: the data comes from Dongfang fortune.com; the enterprise classification is based on tongdaxin for reference There is a hidden worry According to the comparison between the revenue data and the net profit data, it is found that the overall growth rate of the operating revenue has reached more than 20% and the slowest pharmaceutical business has also reached 15.45% However, the growth rate of net profit is unsatisfactory Except that the growth rate of health care is over 50% year-on-year and the growth rate of pharmaceutical business is 11.26%, the growth rate of other sub industries is not optimistic Biopharmaceuticals, driven by Shanghai Laishi, which has huge losses in stock speculation, has seen a decline in net profit The overall growth rate of net profit is less than half of the growth rate of operating revenue It can be seen that under the influence of regulatory policies such as medical insurance fee control, auxiliary / monitoring drugs, centralized procurement and so on, the rest of the increase in revenue does not increase profits seriously The rapid growth of business income is due to the results of merger and acquisition of enterprises In the middle of 2018, Chinese patent medicine was the segment with the highest net interest rate Recently, due to the listing of Mindray medical, a unicorn enterprise in the medical device industry, on the growth enterprise market, its net interest rate is up to nearly 30% and its net profit is large, which drives the net interest rate of the whole medical and health care industry (Note: tongdaxin classifies the medical device industry as health care) to rise rapidly, replacing the first Chinese patent medicine industry in the mid-2018 market In the past, the biopharmaceutical industry generally ranked first in net interest rate, but this year, the leading biopharmaceutical enterprise, Shanghai Laishi, suffered a huge loss, resulting in a sharp drop of nearly 7 percentage points in its net profit margin year on year ▍ these pharmaceutical enterprises are expected to earn more than 3 billion yuan in the whole year Among 281 pharmaceutical enterprises, more than 60% have a net profit of over 100 million yuan, 47 have a net profit of over 500 million yuan, 21 have a net profit of over 1 billion yuan, 9 have a net profit of over 2 billion yuan, and 3 have a net profit of over 3 billion yuan Therefore, it is speculated that there are 7 companies with a net profit of more than 3 billion yuan in the whole year: among them, the top three companies, Kangmei pharmaceutical, Baiyunshan Pharmaceutical and Shanghai Pharmaceutical have a net profit of more than 3 billion yuan, and Hengrui pharmaceutical, Meirui medical, Yunnan Baiyao pharmaceutical and XinHeCheng pharmaceutical have a net profit of more than 2.5 billion yuan in the first three quarters of 2018, with an average net profit of more than 800 million yuan per quarter If there is no accident, the net profit of the whole year can reach more than 3 billion yuan From the perspective of growth, except Yunnan Baiyao, the operating revenue and net profit of other enterprises have both achieved a rapid growth of two percentages Among them, the net profit of XinHeCheng increased nearly 2 times, and Baiyunshan exceeded 1.3 times From the perspective of manager level, due to different industries, there are great differences The net interest rates of XinHeCheng, Hengrui medicine and Meirui medicine are over 20%, while the net interest rates of XinHeCheng are close to 40% Note: the data comes from Dongfang fortune.com; the enterprise classification is based on tongdaxin for reference Among the pharmaceutical enterprises with a net profit of more than 3 billion yuan, Kangmei pharmaceutical and Baiyunshan are two traditional Chinese medicine enterprises It can be seen that although the development of Chinese traditional medicine enterprises, especially injection enterprises, has been limited due to the influence of auxiliary drugs and monitoring drugs in the past two years, they have better integration ability, stronger control ability of upstream raw materials, ability to play scale benefits, and strong ability to make money with traditional Chinese patent medicine enterprises * Kangmei pharmaceutical In spite of recent media reports that Kangmei Pharmaceutical Co., Ltd has suffered from high currency and cash, high deposit and loan, high proportion of major shareholders' stock pledge and high gross profit rate of traditional Chinese medicine trade, and its stock price has nearly halved, its performance is quite beautiful: in the first three quarters of 2018, Kangmei Pharmaceutical Co., Ltd achieved a total revenue of 25.428 billion yuan, an increase of 30.11% over the same period of last year, and a net profit of 3.831 billion yuan, a year-on-year increase of 30.11% In the same period, it increased by 22.10% Focusing on the two development themes of the whole industry chain of traditional Chinese medicine and the big health industry, Kangmei pharmaceutical industry has built a precise service-oriented "wisdom + big health" industry service system of the whole industry chain of traditional Chinese medicine to promote the upgrading of the big health industry Expand the business beyond the main business Make full use of the market opportunities brought by a series of policies such as drug consistency evaluation and two vote system, integrate high-quality resources in various ways such as investment, merger and acquisition, build the company's regional medical device sales platform, quickly obtain GSP qualification, expand the medical and medical device distribution business; invest and manage public hospitals to supplement the company's medical resources and seize the medical terminal market In the first three quarters of 2018, Baiyunshan achieved an operating revenue of 29.876 billion yuan, a year-on-year increase of 87.11%; and a net profit of 3.439 billion yuan, a year-on-year increase of 131.50% There are three main reasons for the large increase ① Guangzhou Pharmaceutical Co., Ltd ("pharmaceutical company") and Guangzhou Wanglaoji Pharmaceutical Co., Ltd ("Wanglaoji pharmaceutical") were incorporated into the scope of the merger, resulting in a substantial increase in revenue and net profit ② increase market expansion and achieve rapid development of many large varieties The sales of Jinge, Banlangen Granules, Guanghua Xiaochaihu granules, pan Gaoshou honey refined Chuanbei Pipa cream, Chen Liji Zhuangyaojianshen pills and other key varieties recorded a significant increase ③ capital investment gains value-added income The company participated in the non-public issuance of shares of Yixintang company, with a value-added of RMB 255 million included in the profits in 2018, which increased the profits of the current period The main business of SHP continues to grow rapidly In the first three quarters, the operating revenue has exceeded 100 billion yuan, with a year-on-year growth of 18.75%, and the net profit of 3.372 billion yuan, with a year-on-year growth of 25.21% The growth rate of net profit is higher than that of income Among them, the sales revenue of the pharmaceutical industry was 14.254 billion yuan, an increase of 27.80% over the same period last year, of which the sales revenue of 60 key varieties from January to September was 7.569 billion yuan The company is also increasing R & D investment From January to September, it invested nearly 800 million yuan in R & D, and actively promoted the consistency evaluation All 12 regulations have completed be test and applied to the State Food and drug administration 48 regulations are in the clinical research stage In terms of pharmaceutical business, the company's pharmaceutical distribution business achieved a sales revenue of 103.058 billion yuan from January to September, a year-on-year increase of 16.94%; the pharmaceutical retail business achieved a sales revenue of 5.096 billion yuan, a year-on-year increase of 24.05% The company is also actively seeking to become the national general agent of innovative imported drugs In the first three quarters of this year, the company obtained 12 national general agents of imported new drugs, including the star drug of MSD PD-1, keytruda, and Squibb's opdivo Odevo's sales revenue has reached 190 million yuan, and coreda's sales revenue is 150 million yuan In the first three quarters of 2018, Hengrui pharmaceutical has achieved sales revenue of 12.458 billion yuan, a year-on-year increase of 23.77% It is estimated that the annual actual sales revenue is about 16 billion yuan, and the net profit is 2.912 billion yuan, a year-on-year increase of 25.10% The growth rate of net profit should be higher than that of income Under the influence of two vote system, centralized procurement and other policy measures, it is not easy for an enterprise to keep its net profit and income growing at the same time, and it is difficult for an enterprise to achieve the growth rate of net profit exceeding that of income It can be seen that pharmaceutical enterprises with leading R & D strength have outstanding value advantages in the operation process, with stronger profitability and the ability to resist external policies, measures and risks * Mindray medical is another Unicorn enterprise in A-share industry after Wuxi apptec It was officially listed on the growth enterprise market of Shenzhen Stock Exchange in mid October Mindray medical is the leading enterprise of medical devices in China In the first three quarters of 2018, Mindray medical realized sales revenue of 10.28 billion yuan, a year-on-year increase of 23.19%, net profit of 2.897 billion yuan, a year-on-year increase of 45.25% It is estimated that the annual revenue will exceed 13 billion yuan and the net profit will exceed 3.3 billion yuan There are two main reasons for the growth of Meirui's medical performance: one is to continuously increase market development, achieve a higher growth in product sales, and steadily increase sales revenue; the other is to focus on the main business, control costs and reduce costs, improve management efficiency, expand scale effect, and achieve a faster growth in the company's performance Yunnan Baiyao, which has been trapped in the whirlpool of "carbamic acid" added to toothpaste recently, is an important member of the Chinese traditional medicine market Although it is not as old as Tongrentang in history, its commercialization is relatively successful In recent years, it has achieved cross-border development, and its business scale and performance continue to expand In the first three quarters of 2018, Yunnan Baiyao achieved a sales revenue of 19.724 billion yuan, a year-on-year increase of 9.53%, and a net profit of 2.732 billion yuan, a year-on-year increase of 4.88% ※ new Hecheng company strictly implemented the business plan formulated at the beginning of the year All works were implemented effectively, achieving steady growth of business performance In the first three quarters, it realized operating revenue of 6.719 billion yuan, a year-on-year increase of 64.20%; net profit of 2.537 billion yuan, a year-on-year increase of 181.60% The main reasons for the company's sustained growth and significant increase in net profit are as follows: ① adhering to the marketing concept of "creating demand and serving customers", the business has achieved significant growth, and the company's fragrance business and nutrition business have increased significantly compared with the same period of last year ② Since 2017, the price of vitamins has continued to rise, with supply exceeding demand and net profit significantly increased.